Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zepp Health (ZEPP) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Zepp Health (ZEPP) over the last 8 years, with Sep 2025 value amounting to $61.7 billion.

  • Zepp Health's Cash & Equivalents fell 45.94% to $61.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $61.7 billion, marking a year-over-year decrease of 45.94%. This contributed to the annual value of $91.1 million for FY2024, which is 31.87% down from last year.
  • Per Zepp Health's latest filing, its Cash & Equivalents stood at $61.7 billion for Q3 2025, which was up 11.32% from $55.4 billion recorded in Q2 2025.
  • Over the past 5 years, Zepp Health's Cash & Equivalents peaked at $215.7 billion during Q2 2021, and registered a low of $91.1 million during Q4 2024.
  • For the 3-year period, Zepp Health's Cash & Equivalents averaged around $86.9 billion, with its median value being $114.2 billion (2024).
  • In the last 5 years, Zepp Health's Cash & Equivalents plummeted by 93.41% in 2021 and then surged by 96,759.64% in 2022.
  • Quarterly analysis of 5 years shows Zepp Health's Cash & Equivalents stood at $230.4 million in 2021, then tumbled by 44.22% to $128.6 million in 2022, then grew by 3.98% to $133.7 million in 2023, then slumped by 31.87% to $91.1 million in 2024, then slumped by 45.94% to $61.7 billion in 2025.
  • Its Cash & Equivalents stands at $61.7 billion for Q3 2025, versus $55.4 billion for Q2 2025 and $76.4 billion for Q1 2025.